Medgend Icon

Ledgend of Medicine







discontinued


Able

What is diabetes?

Diabetes, also known as diabetes mellitus, is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose is your body's main source of energy. Your body can make glucose, but it also comes from the food you eat. Insulin is a hormone made by your pancreas. Insulin helps move glucose from your bloodstream into your cells, where it can be used for energy.

If you have diabetes, your body can't make insulin, can't use insulin as well as it should, or both. Too much glucose stays in your blood and doesn't reach your cells. This can cause glucose levels to get too high. Over time, high blood glucose levels can lead to serious health conditions. But you can take steps to manage your diabetes and try to prevent these health problems.

What are the types of diabetes?

There are different types of diabetes:

  • Type 1 diabetes. If you have type 1 diabetes, your body makes little or no insulin. It happens when your immune system attacks and destroys the cells that produce insulin.
  • Type 2 diabetes. This is the most common form of diabetes. If you have type 2 diabetes, your body may still be able to make insulin, but your cells don't respond well to insulin. They can't easily take up enough glucose from your blood.
  • Gestational diabetes. This is a form of diabetes that develops during pregnancy. It happens when your body can't make the extra insulin it needs during pregnancy.
What causes diabetes?

The different types of diabetes have different causes:

  • Researchers think type 1 diabetes is caused by genes and factors in the environment that might trigger the disease.
  • Type 2 diabetes is caused by several factors, including lifestyle factors and genes. The lifestyle factors include not being physically active and being overweight or having obesity.
  • Researchers think gestational diabetes is caused by the hormonal changes of pregnancy along with genetic and lifestyle factors.
Who is more likely to develop diabetes?

The different types of diabetes have different risk factors:

  • You can develop type 1 diabetes at any age, but it most often starts in childhood. Having a parent or sibling with type 1 diabetes may increase your chance of developing it.
  • You are at higher risk of developing type 2 diabetes if you:
    • Are overweight or have obesity.
    • Are over age 35. Children, teenagers, and younger adults can get diabetes, but it is more common in middle-aged and older adults.
    • Have a family history of diabetes.
    • Have prediabetes. This means that your blood glucose is higher than normal, but it's not high enough to be called diabetes.
    • Had gestational diabetes.
    • Have given birth to a baby weighing 9 pounds or more.
    • Are African American, American Indian, Asian American, Hispanic/Latino, or Pacific Islander.
    • Are not physically active.
    • Have certain other health conditions, such as high blood pressure or polycystic ovary syndrome (PCOS).
  • You are at higher risk of developing gestational diabetes if you:
    • Are overweight or have obesity.
    • Have a family history of diabetes.
    • Had gestational diabetes in a previous pregnancy.
    • Have given birth to a baby weighing 9 pounds or more.
    • Have polycystic ovary syndrome (PCOS).
    • Are African American, Hispanic/Latino, American Indian, Alaska Native, Native Hawaiian, or Pacific Islander.
What are the symptoms of diabetes?

The symptoms of diabetes may include:

  • Feeling very thirsty
  • Feeling very hungry
  • Urinating (peeing) more often, including at night
  • Fatigue
  • Blurry vision
  • Numbness or tingling in the feet or hands
  • Sores that do not heal
  • Losing weight without trying

But it's important to know that your symptoms may vary, depending on which type you have:

  • The symptoms of type 1 diabetes usually come on quickly and can be severe.
  • With type 2 diabetes, the symptoms often develop slowly, over several years. The symptoms can be so mild that you might not even notice them.
  • Gestational diabetes often has no symptoms. If you do have symptoms, they may be mild. If you are pregnant, you will usually be screened for this condition between 24 and 28 weeks of pregnancy.
How is diabetes diagnosed?

To find out if you have diabetes, your health care provider will use one or more glucose blood tests. There are several types, including the A1C test.

What are the treatments for diabetes?

Treatment for diabetes involves managing your blood glucose levels:

  • If you have type 1 diabetes, you will need to take daily doses of insulin, either by injection or through a special pump. Some people also need to take another type of diabetes medicine that works with insulin.
  • If you have type 2 diabetes, you may be able to manage or even reverse it by making lifestyle changes. These include eating a healthy diet, staying at healthy weight, and getting regular physical activity. Some people also need to take diabetes medicines to manage their diabetes.
  • If you have gestational diabetes, you may be able to lower your glucose levels by eating a healthy diet and getting regular exercise. But be sure to talk to your provider about your treatment options. Gestational diabetes usually goes away after you give birth. But you will have a higher risk of developing type 2 diabetes later.

Checking your blood glucose levels is also an important part of managing your diabetes. Ask your provider about the best way to check your blood glucose level and how often you should check it.

Can diabetes be prevented?

Type 1 diabetes can't be prevented.

You may be able to delay or prevent type 2 diabetes through the same lifestyle changes that are used to manage diabetes (eating a healthy diet, staying at a healthy weight, and getting regular physical activity). These lifestyle changes may also help prevent gestational diabetes.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Able FDA Approved Drugs

ABILIFY MAINTENA KIT [AripiprazoleC23H27Cl2N3O2]
RX
-
300mg (intramuscular for suspension, extended release)
300mg/vial (intramuscular for suspension, extended release)
400mg (intramuscular for suspension, extended release)
400mg/vial (intramuscular for suspension, extended release)
Otsuka Pharm Co LtdSep 29, 2014
  • Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia.
  • Treatment of schizophrenia.
  • Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia.
  • Use of aripiprazole in extended release injectable suspension.
efficacy
3.5  (2)
side effects
5.0  (1)
danger
1.0  (1)

UNK

ADDYI [FlibanserinC20H21F3N4O]
RX
-
100mg (oral tablet)
Sprout PharmsAug 18, 2015
  • Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd).
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

AFINITOR [EverolimusC53H83NO14]
RX
-
10mg (oral tablet)
2.5mg (oral tablet)
7.5mg (oral tablet)
NovartisMar 30, 2009
  • Treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.
  • Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic.
  • Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected..
  • Treatment of solid excretory system tumors; advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib.
efficacy
2.0  (2)
side effects
0.0  (0)
danger
0.0  (0)

UNK

AMITIZA [LubiprostoneC20H32F2O5]
RX
-
24mcg (oral capsule)
8mcg (oral capsule)
Sucampo Pharma LlcJan 31, 2006
  • Method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient.
  • Method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient.
  • Method for relieving or treating constipation in a human constipated patient.
  • Method for relieving or treating constipation in a patient with irritable bowel syndrome.
  • Method for relieving or treating constipation in a patient with opioid-induced constipation.
  • Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome.
  • Method for the long term treatment of chronic constipation in a human subject.
  • Method for treating constipation by opening cic channels in a mammalian subject.
  • Method for treating constipation in a patient with opioid-induced constipation by opening cic channels.
  • Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome.
  • Method for treating opioid-induced constipation.
  • Method of relieving or preventing constipation in a human constipated patient.
  • Method of relieving or preventing constipation in a human patient with opioid-induced constipation.
  • Method of treating constipation in a patient with irritable bowel syndrome by opening chloride channels (cic).
  • Method of treating constipation in a patient with irritable bowel syndrome.
  • Use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient.
  • Use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ARGATROBAN IN SODIUM CHLORIDE [ArgatrobanC23H36N6O5SH2O]
RX
-
125mg/125ml (1mg/ml) (iv (infusion) injectable)
50mg/50ml (1mg/ml) (iv (infusion) injectable)
Gland Pharma LtdMay 22, 2017
SandozMay 9, 2011
Eagle PharmsJun 29, 2011
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BRILINTA [TicagrelorC23H28F2N6O4S]
RX
-
60mg (oral tablet)
90mg (oral tablet)
Astrazeneca PharmsSep 3, 2015
  • Method of inhibiting platelet aggregation.
  • Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction.
  • Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
  • Reduction of the rate of thrombotic events in patients with acute coronary syndrome.
  • Treatment of an arterial thrombotic complication in a patient with coronary artery, cerebrovascular or peripheral vascular disease.
  • Treatment of arterial thrombotic complications selected from the group consisting of unstable angina, thrombotic or embolic stroke, transient ischaemic attacks, peripheral vascular disease and myocardial infarction.
  • Treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
  • Treatment of myocardial infarction in patients with acute coronary syndrome or a history of myocardial infarction.
  • Treatment of myocardial infarction.
  • Treatment of post-myocardial infarction.
  • Treatment of stable and unstable angina.
  • Treatment of stroke in patients with acute coronary syndrome or a history of myocardial infarction.
  • Treatment of stroke.
  • Treatment of thrombotic stroke.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

CLEVIPREX [ClevidipineC21H23Cl2NO6]
RX
-
125mg/250ml (0.5mg/ml) (intravenous emulsion)
25mg/50ml (0.5mg/ml) (intravenous emulsion)
50mg/100ml (0.5mg/ml) (intravenous emulsion)
Chiesi Usa IncNov 8, 2013
  • Cleviprex is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

DARIFENACIN HYDROBROMIDE [Darifenacin HydrobromideC28H30N2O2BrH]
RX
-
eq 15mg base (oral tablet, extended release)
eq 7.5mg base (oral tablet, extended release)
Anchen PharmsMar 13, 2015
Aurobindo Pharma LtdSep 19, 2016
Cipla LtdSep 1, 2016
Jubilant GenericsOct 12, 2016
Torrent Pharms LtdNov 17, 2016
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

DIOVAN [ValsartanC24H29N5O3]
RX
-
160mg (oral tablet)
320mg (oral tablet)
40mg (oral tablet)
80mg (oral tablet)
NovartisJul 18, 2001
  • Treatment of hypertension.
  • Use of valsartan to reduce cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

DORYX [Doxycycline Hyclate2C22H24N2O8C2H6O2ClHH2O]
RX
-
eq 100mg base (oral tablet, delayed release)
eq 150mg base (oral tablet, delayed release)
eq 200mg base (oral tablet, delayed release)
eq 50mg base (oral tablet, delayed release)
eq 75mg base (oral tablet, delayed release)
eq 80mg base (oral tablet, delayed release)
Mayne PharmaMay 6, 2005
  • To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

DORYX MPC [Doxycycline Hyclate2C22H24N2O8C2H6O2ClHH2O]
RX
-
eq 120mg base (oral tablet, delayed release)
eq 60mg base (oral tablet, delayed release)
Mayne PharmaMay 20, 2016
  • To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ENABLEX [Darifenacin HydrobromideC28H30N2O2BrH]
RX
-
eq 15mg base (oral tablet, extended release)
eq 7.5mg base (oral tablet, extended release)
ApilDec 22, 2004
  • Treating urinary incontinence by administering an extended-release form of darifenacin.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

EXONDYS 51 [Eteplirsen]
RX
-
100mg/2ml (50mg/ml) (iv (infusion) solution)
500mg/10ml (50mg/ml) (iv (infusion) solution)
Sarepta Theraps IncSep 19, 2016
  • (i)treatment of duchenne muscular dystrophy; (ii)restoring/increasing functional dystrophin protein; or (iii) inducing skipping; each of (i)-(iii) in patients having a confirmed mutation of the dmd gene that is amenable to exon 51 skipping.
  • Restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping.
  • Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

FARXIGA [Dapagliflozin PropanediolC21H25ClO6C3H8O2H2O]
RX
-
eq 10mg base (oral tablet)
eq 5mg base (oral tablet)
Astrazeneca AbJan 8, 2014
  • Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone.
  • Treatment of type 2 diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

FLOVENT HFA [Fluticasone PropionateC25H31F3O5S]
RX
-
0.044mg/inh (inhalation aerosol, metered)
0.11mg/inh (inhalation aerosol, metered)
0.22mg/inh (inhalation aerosol, metered)
Glaxo Grp LtdMay 14, 2004
  • Method of treating a condition capable of treatment by inhalation, e.g. asthma, comprising administration of a formulation claimed in us patent no. 6743413.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

GLEEVEC [Imatinib MesylateC29H31N7OCH4O3S]
RX
-
eq 100mg base (oral tablet)
eq 400mg base (oral tablet)
NovartisApr 18, 2003
  • A method for treating a tumor disease.
  • Gleevec is also indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist).
  • Treatment of gastrointestinal stromal tumors (gist).
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HALAVEN [Eribulin MesylateC40H59NO11CH4O3S]
RX
-
1mg/2ml (0.5mg/ml) (intravenous solution)
Eisai IncNov 15, 2010
  • Treatment of patients with metastatic breast cancer.
  • Treatment of patients with unresectable or metastatic liposarcoma.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMALOG KWIKPEN [Insulin Lispro Recombinant]
RX
-
100 units/ml (injection injectable)
200 units/ml (subcutaneous solution)
LillySep 6, 2007
Eli Lilly And CoMay 26, 2015
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

IXEMPRA KIT [IxabepiloneC27H42N2O5S]
RX
-
15mg/vial (iv (infusion) injectable)
45mg/vial (iv (infusion) injectable)
R-pharm Us LlcOct 16, 2007
  • A method of treating cancer in a patient comprising administering ixabepilone or pharmaceutical compositions comprising ixabepilone.
  • Method of treating breast cancer by administering ixabepilone; a method of treating a cancer responsible to microtubule stabilization by administering ixabepilone.
  • Method of treating cancer in a patient comprising intravenously administering to the patient ixabepilone diluted in a parenteral diluent.
  • Method of treating cancer, iv admin, lyophylized ixabepilone diluted, every week or 3 weeks; lyophilized ixabepilone with solvent(dehydrated ethanol) diluted to concentration of 0.1mg/ml to 0.9mg/ml.
  • Method of treating patient comprising mixing first and second vials of product comprising lyophilized ixabepilone to provide an epothilone analog solution, diluting solution with a suitable diluent to prepare intravenous formulation for pt.
  • Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LEVITRA [Vardenafil HydrochlorideC23H32N6O4SClH3H2O]
RX
-
10mg (oral tablet)
2.5mg (oral tablet)
20mg (oral tablet)
Bayer HlthcareAug 19, 2003
  • Erectile dysfunction.
  • Treatement of erectiile dysfunction by administering a film-coated tablet.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LINZESS [LinaclotideC59H79N15O21S6]
RX
-
145mcg (oral capsule)
290mcg (oral capsule)
72mcg (oral capsule)
Forest Labs LlcAug 30, 2012
  • Method of treating chronic idiopathic constipation in adult patients..
  • Method of treating irritable bowel syndrome with constipation in adult patients..
  • Method of treating irritable bowel syndrome with constipation in adults.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

MEKINIST [Trametinib Dimethyl SulfoxideC26H23FIN5O4C2H6OS]
RX
-
eq 0.5mg (oral tablet)
eq 1mg (oral tablet)
eq 2mg (oral tablet)
Novartis Pharms CorpMay 29, 2013
  • In combination with dabrafenib for the treatment of unresectable or metastatic melanoma..
  • Mekenist in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma.
  • Treatment of unresectable or metastatic melanoma.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

MULTAQ [Dronedarone HydrochlorideC31H44N2O5SClH]
RX
-
eq 400mg base (oral tablet)
Sanofi Aventis UsJul 1, 2009
  • Management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af.
  • Reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a daily with morning and evening meals.
  • Reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals.
  • Reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals.
  • Reduction of the risk of cardiovascular hospitalization.
  • Reduction of the risk of hospitalization for atrial fibrillation.
  • Treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NEUPRO [RotigotineC19H25NOS]
RX
-
1mg/24hr (transdermal film, extended release)
2mg/24hr (transdermal film, extended release)
3mg/24hr (transdermal film, extended release)
4mg/24hr (transdermal film, extended release)
6mg/24hr (transdermal film, extended release)
8mg/24hr (transdermal film, extended release)
Ucb IncApr 2, 2012
  • A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient.
  • Treatment of restless legs syndrome by application of claimed transdermal delivery system.
  • Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NEXAVAR [Sorafenib TosylateC21H16ClF3N4O3C7H8O3S]
RX
-
eq 200mg base (oral tablet)
Bayer HlthcareDec 20, 2005
  • Treatment of advanced renal cell carcinoma.
  • Treatment of carcinoma of the thyroid.
  • Treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, or differentiated thyroid carcinoma..
  • Treatment of unresectable hepatocellular carcinoma.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ORENITRAM [Treprostinil DiolamineC23H34O5C4H11NO2]
RX
-
eq 0.125mg base (oral tablet, extended release)
eq 0.25mg base (oral tablet, extended release)
eq 1mg base (oral tablet, extended release)
eq 2.5mg base (oral tablet, extended release)
eq 5mg base (oral tablet, extended release)
United TherapDec 20, 2013
  • Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically acceptable salt of treprostinil.
  • Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1)..
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

QUILLICHEW ER [Methylphenidate HydrochlorideC14H19NO2ClH]
RX
-
20mg (oral tablet, extended release, chewable)
30mg (oral tablet, extended release, chewable)
40mg (oral tablet, extended release, chewable)
Pfizer IncDec 4, 2015
  • A method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet according to claim 1.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

RAYOS [PrednisoneC21H26O5]
RX
-
1mg (oral tablet, delayed release)
2mg (oral tablet, delayed release)
5mg (oral tablet, delayed release)
Horizon PharmaJul 26, 2012
  • Treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet.
  • Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet.
  • Treatment of pulmonary, gastrointestinal and/or rheumatological diseases or conditions by use of delayed release formulations of 1mg or 2mg prednisone.
  • Treatment of rheumatoid arthritis by delayed release formulation of 1mg or 2mg of prednisone.
  • Treatment of rheumatologic, allergic, pulmonary, gastrointestinal, dermatologic diseases or conditions by the use of a delayed release 5mg prednisone tablet.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

REBETOL [RibavirinC8H12N4O5]
RX
-
200mg (oral capsule)
40mg/ml (oral solution)
Merck Sharp DohmeJul 25, 2001
ScheringJul 29, 2003
  • Method of treating hepatitis c viral infection by continuous parenteral admin interferon alpha 2-10 million iu weekly, subcutaneously, injection of polymer-interferon alpha conjugate-polymer is peg-interferon is alpha 2b.
  • Method of treating pt with chronic hepatitis c having hcv genotype 1 and viral load greater than 2 million copies/ml to eradicate detectable hcv-rna by admin combination of ribavirin and interferon alfa-2b for a least 24 weeks.
  • Method of tx a pt suspected of having hepatitis c by admin, in combination, a conjugate comprising peg 12000 & interferon alfa-2b in an amt of from 0.5mcg/kg to 2mcg/kg, once weekly, and ribavirin.
  • Method of using peg-intron/rebetol combination therapy and intron/rebetol combination therapy.
  • Method of using rebetol capsules in combination with a conjugate comprising polyethylene glycol(peg) and an alpha interferon, including, for example, peg-intron powder for injection.
  • Method of using ribavirin in combination with interferon alpha-2b(pegylated and nonpegylated) to treat patients with chronic hepatitis c.
  • Method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

RYTARY [CarbidopaC10H14N2O4H2O : LevodopaC9H11NO4]
RX
-
23.75mg : 95mg (oral capsule, extended release)
36.25mg : 145mg (oral capsule, extended release)
48.75mg : 195mg (oral capsule, extended release)
61.25mg : 245mg (oral capsule, extended release)
Impax Labs IncJan 7, 2015
  • Method of providing a therapeutically effective and stable median blood plasma level of levodopa.
  • Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
  • Treatment of parkinson's disease.
  • Treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
  • Treatment of post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
  • Treatment of post-encephalitic parkinsonism.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SPIRIVA [Tiotropium Bromide]
RX
-
eq 0.018mg base/inh (inhalation powder)
Boehringer IngelheimJan 30, 2004
  • Administration of an inhalable powder comprising tiotropium via device.
  • For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema.
  • Treatment of chronic obstructive pulmonary disease.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TAFINLAR [Dabrafenib MesylateC23H20F3N5O2S2CH4O3S]
RX
-
eq 50mg base (oral capsule)
eq 75mg base (oral capsule)
Novartis Pharms CorpMay 29, 2013
  • Tafinlar in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma.
  • Treatment of melanoma.
  • Treatment of patients with unresectable or metastatic melanoma with braf v600e mutations after confirming the presence of braf v600e mutation.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TARCEVA [Erlotinib HydrochlorideC22H23N3O4ClH]
RX
-
eq 100mg base (oral tablet)
eq 150mg base (oral tablet)
eq 25mg base (oral tablet)
Osi PharmsNov 18, 2004
  • First-line treatment of locally advanced unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
  • First-line treatment of metastatic non smal-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test.
  • Maintenance treatment in patients with locally advanced or metastatic nsclc who have not progressed on 1st-line treatment wth platinum-based chemotherapy.
  • Maintenance treatment of patients with locally advanced or metastatic nsclc whose disease has not progressed after four cycles platinum-based chemotherapy.
  • Treatment of locally advanced or metastatic non small-cell lung cancer (nsclc) after failure of at least one prior chemotherapy regimen.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

VARITHENA [PolidocanolC12H26O(C2H4O)n]
RX
-
180mg/18ml (10mg/ml) (intravenous solution)
ProvensisNov 25, 2013
  • A method of generating an injectable foam of controlled density and bubble size.
  • A method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities.
  • A method of using a sclerosing agent for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous (gsv) system above and below the knee.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

VIBERZI [EluxadolineC32H35N5O5]
RX
-
100mg (oral tablet)
75mg (oral tablet)
Allergan HoldingsMay 27, 2015
  • Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).
  • Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline)..
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

XARELTO [RivaroxabanC19H18ClN3O5S]
RX
-
10mg (oral tablet)
15mg (oral tablet)
20mg (oral tablet)
Janssen PharmsJul 1, 2011
  • Following initial 6 months treatment for deep vein thrombosis (dvt) and/or pulmonary embolism (pe), reduction in the risk of recurrence of dvt and of pe with once daily, rapid-release tablet administered for at least five consecutive days.
  • Prophylaxis of deep vein thrombosis (dvt).
  • Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days.
  • Reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days.
  • Reducing the risk of stroke and systemic embolism.
  • Reduction in the risk of recurrence of deep vein thrombosis (dvt) and pulmonary embolism.
  • Treatment of deep vein thrombosis (dvt).
  • Treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days.
  • Treatment of pulmonary embolism (pe).
  • Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days.
efficacy
4.0  (1)
side effects
0.0  (0)
danger
0.0  (0)

UNK

XIFAXAN [RifaximinC43H51N3O11]
RX
-
200mg (oral tablet)
550mg (oral tablet)
Salix PharmsMay 25, 2004
  • Method of treating travelers' diarrhea.
  • The treatment of patients with travelers' diarrhea (td) or the reduction in risk of overt hepatic encephalopathy (he) recurrence.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

XIGDUO XR [Dapagliflozin PropanediolC21H25ClO6C3H8O2H2O : Metformin HydrochlorideC4H11N5ClH]
RX
-
eq 10mg base : 1gm (oral tablet, extended release)
eq 10mg base : 500mg (oral tablet, extended release)
eq 5mg base : 1gm (oral tablet, extended release)
eq 5mg base : 500mg (oral tablet, extended release)
Astrazeneca AbOct 29, 2014
  • Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone.
  • Treatment of type 2 diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ZELBORAF [VemurafenibC23H18ClF2N3O3S]
RX
-
240mg (oral tablet)
Hoffmann La RocheAug 17, 2011
  • Treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ZINGO [Lidocaine HydrochlorideC14H22N2OClHH2O]
RX
-
0.5mg (intradermal system)
Powder PharmsAug 16, 2007
  • Zingo intradermal injection system is a drug delivery system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action.
  • Zingo is a powder intradermal system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.


WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for reference only. Many of these treatments may be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field. The owner of this website will not be held liable for any injuries and deaths cause by following any home remedies. We have no control of what is posted.

Home Remedies for Able

HICCUPS [intractable hiccups]
   Consume 1 to 2 teaspoons of sugar.Sillygirl | November 5th, 2017
efficacy
4.0  (1)
side effects
2.0  (1)
danger
3.0  (2)

UNK

FEVER
   Steep 1 tablespoon of dried linden flower in a cup of hot water for 15 minutes. Drink 3 to 4 cups per day. Seek medical help if your fever last more than 1 day. For fever above 102F, take lukewarm bath to reduce temperature below 102F.LoisaAllcott | November 4th, 2017
efficacy
3.0  (2)
side effects
2.0  (1)
danger
2.5  (2)

UNK

SORE THROAT [pharyngitis]
   Ulmus fulva, known as Slippery elm, has been used to treat a sore throat or inflamed mouth or intestines. Slippery elm bark has been used by american indians to treat a sore throat since the early 1800s.

In a cup, use boiling water to steep 1 tablespoon of Slippery elm bark powder for 10 minutes. Gargle and then swallow as needed.

Alternatively, purchase Slippery elm lozenges and consume as directed.Jerry | August 7th, 2020
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SORE THROAT [Pharyngitis]
   Mix 3 tablespoons of Willow bark (Salix spp.) with 1 pint of water. Heat just below boiling for 30 minutes. Let cool. Gargle as needed.Jerry | August 9th, 2020
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SORE THROAT [Pharyngitis]
   Sage leaf (Salvia officinalis) is mixed with boiling water (1 tablespoon sage leaf) in a cup. Let cool and gargle. Do not take concentrated sage essential oil or alcohol tincture while pregnant.TimmyStymn | August 9th, 2020
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SORE THROAT [Pharyngitis]
   ...Boil 1/2 ounce of licorice in 1 quart of water, uncovered, until half of the water is still remaining. Let cool. Drink over a span of a day. Acceptable to repeat for up to 3 days. Do not take licorice if you are pregnant, taking steroids or have low potassium levels. Low potassium levels can ca......al heart rhythms, high blood pressure, edema, lethargy, and/or congestive heart failure. The NIH has determined that there is insufficient data available to know if licorice is effective in treating any medical condition.

The FDA notes:
-Don’t eat large amounts of black licorice at one time...
Mechanism - glycyrrhizin
Jlaiii | August 11th, 2020
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SORE THROAT [Pharyngitis]
   Horehound (Marrubium vulgare) has been used to treat coughs for a long time. Steep 1 tablespoon of horehound in a cup of boiling water for 15 minutes. Gargle with the strained tea. Sweeten with honey if desired. Alternatively, Horehound cough drops can be purchased commercially. Use as directed.Antonchekov | August 11th, 2020
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SORE THROAT [Pharyngitis]
   Steep 3 tablespoons of oak bark (Quercus spp.) in boiling water for 20 minutes. After the tea has been removed and strained, gargle with 2 tablespoons up to 4 times a day.
Mechanism - tannins
Jlaiii | August 11th, 2020
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SORE THROAT [Pharyngitis]
   Red root (Ceanothus americanus) contains ceanothic acid and ceanothetric acid which have been claimed to inhibit Streptococcus bacteria growth in tincture form. To make Red root tea, heat 1 pint of water just below boiling and add 1 ounce of red root. Heat for 20 minutes. Let cool. Gargle with 1 tablespoon, then swallow. Repeat for a total of 4 times a day.
Mechanism - ceanothine A-E, pandamine, zizyphine, scutianine, adouetines
GuydeMaupassant | August 11th, 2020
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TOE NAIL FUNGUS [Onychomycosis]
   The only real "cure" is taking Lamisil (terbinafine hydrochloride) tablets prescribed by a doctor. The longer durations (at weaker doses) allow the nail to grow out. However, this medication can damage your liver. Once the initial infection is under control, brush Vicks Vaporub (or generic) under and around the nail with a toothbrush twice a day to reduce the chance of coming back.Sleslie | July 26th, 2021